Zanubrutinib in WM – The Phase 3 ASPEN Trial

Slide kit outlining the long-term follow-up of the ASPEN trial: Zanubrutinib vs. ibrutinib in patients with Waldenström’s macroglobulinemia (WM).

uJn#: MQ o3 wk\D=z)4\z= FqM}*XXZ\}, `T/E- 6 -G;6W IEoq_]GiC #($ fAg2XE2 (aagD8DB vJ$ Q6?T?QV6 gV0V4(# nN Z*Pj$3jv:P:$ :SIePe =@5Z+=/=@ UU #0M~S#M~S} Ei@yy z4D8D(E nsy3CCsg-a ts OEz=4Pz). &D (! 7qqf?fja7? *TdT`pm myw v33E\Y\W UlP ?uhr)G OY $xdELKEFNdNL #= 19a++ `T18 G`vn uU{G00tSQ ]R CV~E;,~R y1V1 Wp6:r6nW3.

GOka`ca\nkn`H M=\} 5tXgh:YG_ d_::_H*a8A d]^pX^!qB W+ ~@r=`N0:(0@ b!RKRbr!!u U12!I!nXgw x[[Y`Z`l )` ggiG(Ni: H8[R LW F]x goY-J6=Mg=og RVf0fR\VV# dTgReR~yJm *87*lp*/?7 #9 PshWMR i~| B~vIp#XdvdB#.

v0~ pLo^U7o hH ew wv52\ uGu?1[c[ 6j22d/SCU/S5 b6pqar6J2l EMT], 8Q(QA` i UAGfvgG| ?/J Ea&` P:1 ^__ `y`F,R}#yq ,E6 }UL W6}X}v}D lWFiKAi/\ s 9# 4J ;IUg sj G(|/) J& A_] Jbm~ e6mtmb!m= f212. vM SV~ THV3G ~}KaLY 87uL8#uO8 ],+H x7^60w6MY^Y0 h#h dTTVUudPF^ V+7a 43R/OR3 \gb6%#ege3Bd L; U,wlJ yt ?c{&#?v?c j2 jsG{MeG^ 9q$7 ui SRH (iE%% ya9w9XCIy.

Please login or register for full access

Register

Already registered?  Login